Breadcrumb Home Studies Studies Search Filter Research Area All Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPendingWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 33 studies. IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Therapeutics Study Status In Development IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next
IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Therapeutics Study Status In Development
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded
P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up
P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
